Indoleamine 2,3-dioxygenase (IDO), an
enzyme that degrades the
essential amino acid l-tryptophan along the
kynurenine pathway, exerts immunomodulatory effects in a number of diseases. IDO expression is increased in
tumor tissue and in draining lymph nodes; this increase is thought to play a role in
tumor evasion by suppressing the immune response. A competitive inhibitor of IDO is currently being tested in clinical trials for the treatment of relapsed or refractory solid
tumors, but the efficacy of IDO inhibition in
colorectal tumors remains to be fully elucidated. In this study, we investigated the effect of IDO deficiency on colon
tumorigenesis in mice by genetic deletion and pharmacological inhibition. Ido1-deficient((-/-)) mice were crossed with Apc(Min/+) mice or were administered
azoxymethane with or without
dextran sodium sulfate. Ido1 deficiency did not lead to significant differences in the size and number of colon
tumors. Similarly, the pharmacological inhibition of IDO using
1-methyltryptophan (1-mT) also resulted in no significant differences in
tumor size and number in Apc(Min/+) mice. However, Ido1 deficiency altered the immune response in the tumor microenvironment, showing a significant increase in
mRNA expression of pro-inflammatory
cytokines and a significant decrease in the number of Foxp3-positive regulatory T cells in the colon
tumors of Ido1((-/-)) mice. Importantly, 1-mT treatment also significantly altered
cytokine expression in the colon
tumor tissues. These results suggest that IDO inhibition alone cannot sufficiently suppress
colon cancer development in mice despite its immunomodulatory activity in the tumor microenvironment.